title: After EMPA-REG OUTCOME and LEADER: Already a "New Era" in Therapy of Type 2 Diabetes?
abstract: Critical discussion of the cardiovascular findings with empagliflozin (EMPA-REG OUTCOME Study)and liraglutide (LEADER Study) and the consequences.
authors.affiliation: Ruhr University Bochum.
authors.forename: H
authors.initials: H
authors.lastname: Schatz
mesh_terms: D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D005960:Glucosides / Q000627:therapeutic use*; D006801:Humans; D000069450:Liraglutide / Q000627:therapeutic use*
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D000069450:Liraglutide; C570240:empagliflozin